Entering text into the input field will update the search result below

Bavarian Nordic plans to initiate Phase 3 trial of RSV vaccine candidate

  • Bavarian Nordic (OTCPK:BVNRY) announces its commitment to initiate a Phase 3 clinical trial of its RSV vaccine candidate, MVA-BN RSV in H1 2022.
  • The Phase 3 trial is expected to enroll up to 20,000 subjects and run over the course of

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.